Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alocyte for Facetogenic Back Pain
NCT05909709Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Alocyte in Facet Joint Disorder (3 arms). Primary endpoints: Adverse Events at 13 months, Adverse Events assessed by Complete Blood Count at 6 months and 3 more. Started Apr 2024; status: recruiting.
02
Drugs
Alocyte
03
Conditions
Facet Joint Disorder
Beyond the preview
Go deeper on NCT05909709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909709.